Acticor Biotech (France) Executives
| ALACT Stock | EUR 0.27 0.01 3.57% |
Acticor Biotech employs about 25 people. The company is managed by 16 executives with a total tenure of roughly 70 years, averaging almost 4.0 years of service per executive, having 1.56 employees per reported executive. Discussion of Acticor Biotech's management performance can provide insight into the enterprise performance.
| Julien Parrou Chairman Chairman of the Board, Chief Executive Officer |
Acticor |
Acticor Biotech Management Team Effectiveness
The company has return on total asset (ROA) of (0.6851) % which means that it has lost $0.6851 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (3.3291) %, meaning that it generated substantial loss on money invested by shareholders. Acticor Biotech's management efficiency ratios could be used to measure how well Acticor Biotech manages its routine affairs as well as how well it operates its assets and liabilities.Acticor Biotech Workforce Comparison
Acticor Biotech SAS is number one stock in number of employees category among its peers. The total workforce of Communication Services industry is presently estimated at about 11,604. Acticor Biotech adds roughly 25.0 in number of employees claiming only tiny portion of stocks in Communication Services industry.
Acticor Biotech SAS Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Acticor Biotech SAS Price Series Summation is a cross summation of Acticor Biotech price series and its benchmark/peer.
Acticor Biotech Notable Stakeholders
An Acticor Biotech stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Acticor Biotech often face trade-offs trying to please all of them. Acticor Biotech's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Acticor Biotech's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Julien Parrou | Chairman of the Board, Chief Executive Officer | Profile | |
| Patrice Coffe | Administrative and Financial Director, Member of the Board | Profile | |
| Hugues Duboscq | Director - Permanent Representative of Saint-Florentin Participations | Profile | |
| Jerome Leleu | Director | Profile | |
| Frederic Bartoli | Director - Representative of Chorus | Profile | |
| JeanLuc Riviere | Director - Representative of IXO PRIVATE EQUITY | Profile | |
| Gilles MD | CEO Founder | Profile | |
| Eric Cohen | Chief Officer | Profile | |
| Martine MD | Scientific Founder | Profile | |
| Victoria PharmD | Head Assurance | Profile | |
| PharmD Billiald | Scientific Founder | Profile | |
| Sophie LebelBinay | Chief GM | Profile | |
| Laurie Jullien | Head Affairs | Profile | |
| Aymeric Humblot | Head Admin | Profile | |
| Yannick MD | GM Officer | Profile | |
| Kristell Lebozec | Head Devel | Profile |
About Acticor Biotech Management Performance
The success or failure of an entity such as Acticor Biotech SAS often depends on how effective the management is. Acticor Biotech management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Acticor management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Acticor management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Acticor Biotech SAS, a clinical stage biopharmaceutical company, develops drugs for the treatment of acute phase of thrombotic diseases. The company was founded in 2013 and is headquartered in Paris, France. ACTIPLAY is traded on Paris Stock Exchange in France.
Acticor Biotech Workforce Analysis
Traditionally, organizations such as Acticor Biotech use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Acticor Biotech within its industry.Acticor Biotech Manpower Efficiency
Return on Acticor Biotech Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 504.3K | |
| Net Loss Per Executive | 788K |
Additional Tools for Acticor Stock Analysis
When running Acticor Biotech's price analysis, check to measure Acticor Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Acticor Biotech is operating at the current time. Most of Acticor Biotech's value examination focuses on studying past and present price action to predict the probability of Acticor Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Acticor Biotech's price. Additionally, you may evaluate how the addition of Acticor Biotech to your portfolios can decrease your overall portfolio volatility.